{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:43:07Z","timestamp":1793648587503,"version":"4.5.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA233794"],"award-info":[{"award-number":["CA233794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA288375"],"award-info":[{"award-number":["CA288375"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA255621"],"award-info":[{"award-number":["CA255621"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA282178"],"award-info":[{"award-number":["CA282178"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA283935"],"award-info":[{"award-number":["CA283935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008055","name":"Fundaci\u00f3n Eugenio Rodr\u00edguez Pascual","doi-asserted-by":"publisher","award":["2022"],"award-info":[{"award-number":["2022"]}],"id":[{"id":"10.13039\/100008055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008055","name":"Fundaci\u00f3n Eugenio Rodr\u00edguez Pascual","doi-asserted-by":"publisher","award":["FERP 2022"],"award-info":[{"award-number":["FERP 2022"]}],"id":[{"id":"10.13039\/100008055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2022-137181OB-I00"],"award-info":[{"award-number":["PID2022-137181OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2022-136616OB-I00"],"award-info":[{"award-number":["PID2022-136616OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2022-137181OB-I00"],"award-info":[{"award-number":["PID2022-137181OB-I00"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00681"],"award-info":[{"award-number":["PI23\/00681"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00189"],"award-info":[{"award-number":["PI20\/00189"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00526"],"award-info":[{"award-number":["PI22\/00526"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR180016"],"award-info":[{"award-number":["RR180016"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200554"],"award-info":[{"award-number":["RP200554"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["ERC-AdG-2020-101021417"],"award-info":[{"award-number":["ERC-AdG-2020-101021417"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008431","name":"Junta de Castilla y Le\u00f3n Consejer\u00eda de Educaci\u00f3n","doi-asserted-by":"publisher","award":["SA113P23"],"award-info":[{"award-number":["SA113P23"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["PI23\/00681"],"award-info":[{"award-number":["PI23\/00681"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["PI20\/00189"],"award-info":[{"award-number":["PI20\/00189"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["PI22\/00526"],"award-info":[{"award-number":["PI22\/00526"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"COST","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajpath.2024.06.013","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T02:17:40Z","timestamp":1722651460000},"page":"422-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-0326","authenticated-orcid":false,"given":"Rocio I.R.","family":"Macias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5039-9166","authenticated-orcid":false,"given":"Hiroaki","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Berasain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-3557","authenticated-orcid":false,"given":"Matias A.","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.G.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2024.06.013_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186643","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare","volume":"12","author":"Petrick","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2024.06.013_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib6","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.06.013_bib7","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.06.013_bib8","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ajpath.2024.06.013_bib9","first-page":"1187","article-title":"Increased risk of death in thorotrast-exposed patients during the late follow-up period","volume":"78","author":"Kato","year":"1987","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ajpath.2024.06.013_bib10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/gutjnl-2022-327099","article-title":"Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions","volume":"71","author":"Macias","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2024.06.013_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2023.02.027","article-title":"Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma","volume":"79","author":"Lapitz","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/hep.32624","article-title":"Proteogenomic characterization of cholangiocarcinoma","volume":"77","author":"Deng","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.32150","article-title":"The immunogenomic landscape of resected intrahepatic cholangiocarcinoma","volume":"75","author":"Carapeto","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102649","article-title":"Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing","volume":"122","author":"Stenzinger","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ajpath.2024.06.013_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ajpath.2024.06.013_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2024.06.013_bib20","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41467-022-29164-0","article-title":"Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma","volume":"13","author":"Song","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.06.013_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1158\/2326-6066.CIR-21-1101","article-title":"Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis","volume":"10","author":"Bao","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ajpath.2024.06.013_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111384","article-title":"Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis","volume":"40","author":"Keenan","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/cells9030721","article-title":"Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis","volume":"9","author":"Lapitz","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2024.06.013_bib24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.27050","article-title":"Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis","volume":"60","author":"Li","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985089","article-title":"Bile-derived exosome noncoding RNAs as potential diagnostic and prognostic biomarkers for cholangiocarcinoma","volume":"12","author":"Pan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib26","doi-asserted-by":"crossref","first-page":"69995","DOI":"10.18632\/oncotarget.19547","article-title":"The diagnostic\/prognostic potential and molecular functions of long non-coding RNAs in the exosomes derived from the bile of human cholangiocarcinoma","volume":"8","author":"Ge","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2024.06.013_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/diagnostics11060999","article-title":"Diagnostic and prognostic value of circulating cell-free DNA for cholangiocarcinoma","volume":"11","author":"Wintachai","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib28","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.12659\/MSM.895040","article-title":"Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis","volume":"21","author":"Liang","year":"2015","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ajpath.2024.06.013_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10620-014-3472-0","article-title":"Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma","volume":"60","author":"Huang","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajpath.2024.06.013_bib30","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.3748\/wjg.v16.i37.4697","article-title":"Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma","volume":"16","author":"Leelawat","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jhep.2017.06.020","article-title":"Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma","volume":"67","author":"Loosen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib32","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1572-0241.2007.01403.x","article-title":"Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy","volume":"102","author":"Cheon","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib33","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/sj.bjc.6604364","article-title":"MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer","volume":"98","author":"Matull","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.06.013_bib34","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-13-2649","article-title":"Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma","volume":"20","author":"Borger","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.06.013_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.30319","article-title":"Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis","volume":"70","author":"Banales","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/cancers12061433","article-title":"A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma","volume":"12","author":"Macias","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/02841850802220092","article-title":"Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis","volume":"49","author":"Albiin","year":"2008","journal-title":"Acta Radiol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib38","article-title":"Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making","author":"Dhanasekaran","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/cancers16030613","article-title":"Emerging therapies in management of cholangiocarcinoma","volume":"16","author":"Speckart","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib41","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/cells12162098","article-title":"Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2024.06.013_bib42","first-page":"146","article-title":"A case of cancer in which cells similar to those in the tumours were seen in the blood after death","volume":"14","author":"Ashworth","year":"1869","journal-title":"Med J Aust"},{"key":"10.1016\/j.ajpath.2024.06.013_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajpath.2024.06.013_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hep.27944","article-title":"Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma","volume":"63","author":"Yang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.32387","article-title":"Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression","volume":"76","author":"Luo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HEP.0000000000000437","article-title":"Bile exosomal miR-182\/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation","volume":"79","author":"Shu","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib47","article-title":"Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy","volume":"6","author":"Uson Junior","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib48","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.3892\/ol.2017.5991","article-title":"GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma","volume":"13","author":"Liang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ajpath.2024.06.013_bib49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000521613","article-title":"Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma","volume":"11","author":"Lurje","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ajpath.2024.06.013_bib50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7314\/APJCP.2014.15.1.299","article-title":"Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients","volume":"15","author":"Khunluck","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ajpath.2024.06.013_bib51","first-page":"13680","article-title":"Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese population","volume":"8","author":"Meng","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.ajpath.2024.06.013_bib52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1245\/s10434-007-9650-y","article-title":"Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma","volume":"15","author":"Uenishi","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/08941939.2017.1358310","article-title":"Clinical significance of soluble intercellular adhesion molecule-1 and interleukin-6 in patients with extrahepatic cholangiocarcinoma","volume":"31","author":"Shimura","year":"2018","journal-title":"J Invest Surg"},{"key":"10.1016\/j.ajpath.2024.06.013_bib54","doi-asserted-by":"crossref","first-page":"12365","DOI":"10.1007\/s00432-023-05119-w","article-title":"Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma","volume":"149","author":"Tan","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/COC.0000000000000347","article-title":"A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer","volume":"41","author":"Iyer","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1305181","article-title":"Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies","volume":"13","author":"Malkawi","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.941660","article-title":"Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma","volume":"12","author":"Frundt","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901875","article-title":"Exploring circulating tumor cells in cholangiocarcinoma using a novel glycosaminoglycan probe on a microfluidic platform","volume":"9","author":"Gopinathan","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.ajpath.2024.06.013_bib60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1039\/D3LC00862B","article-title":"An integrated microfluidic system for automatic detection of cholangiocarcinoma cells from bile","volume":"24","author":"Chang","year":"2024","journal-title":"Lab Chip"},{"key":"10.1016\/j.ajpath.2024.06.013_bib61","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1002\/ijc.32822","article-title":"A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer","volume":"146","author":"Reduzzi","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2024.06.013_bib62","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/15384047.2018.1480292","article-title":"Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation","volume":"19","author":"Arnoletti","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ajpath.2024.06.013_bib63","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1038\/s41598-017-04056-2","article-title":"A microfluidic chip for detecting cholangiocarcinoma cells in human bile","volume":"7","author":"Hung","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib64","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.30470","article-title":"Bile-derived organoids from patients with primary sclerosing cholangitis recapitulate their inflammatory immune profile","volume":"70","author":"Soroka","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib65","article-title":"Organoids to model liver disease","volume":"3","author":"Nuciforo","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib66","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1002\/ctm2.566","article-title":"Cholangiocyte organoids from human bile retain a local phenotype and can repopulate bile ducts in\u00a0vitro","volume":"11","author":"Roos","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.ajpath.2024.06.013_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.37349\/edd.2024.00037","article-title":"Bile as a liquid biopsy matrix: potential applications and limitations","volume":"3","author":"Arechederra","year":"2024","journal-title":"Explor Dig Dis"},{"key":"10.1016\/j.ajpath.2024.06.013_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajpath.2024.06.013_bib69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12943-019-0980-8","article-title":"Extracellular vesicles in the tumor microenvironment: old stories, but new tales","volume":"18","author":"Han","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2024.06.013_bib70","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14737140.2023.2203386","article-title":"Revision of potential prognostic markers of cholangiocarcinoma for clinical practice","volume":"23","author":"Saengboonmee","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ajpath.2024.06.013_bib71","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/cam4.501","article-title":"Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma","volume":"4","author":"Chaiteerakij","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2024.06.013_bib72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3347\/kjp.2017.55.3.295","article-title":"Subsets of inflammatory cytokine gene polymorphisms are associated with risk of carcinogenic liver fluke opisthorchis viverrini-associated advanced periductal fibrosis and cholangiocarcinoma","volume":"55","author":"Surapaitoon","year":"2017","journal-title":"Korean J Parasitol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib73","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hep.21964","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms","volume":"47","author":"Melum","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib74","first-page":"1341","article-title":"MTHFR polymorphisms and opisthorchis viverrini infection: a relationship with increased susceptibility to cholangiocarcinoma in Thailand","volume":"12","author":"Songserm","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ajpath.2024.06.013_bib75","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.dld.2012.12.017","article-title":"Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma","volume":"45","author":"Krawczyk","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ajpath.2024.06.013_bib76","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1007\/s13277-014-2568-7","article-title":"Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer","volume":"35","author":"Meng","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib77","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2036.2010.04534.x","article-title":"Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma","volume":"33","author":"Mihalache","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajpath.2024.06.013_bib78","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1073\/pnas.81.19.5994","article-title":"T-DNA of agrobacterium tumefaciens encodes an enzyme of cytokinin biosynthesis","volume":"81","author":"Akiyoshi","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.06.013_bib79","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","article-title":"The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.06.013_bib80","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/1078-0432.CCR-23-2693","article-title":"Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types","volume":"30","author":"Kasi","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.06.013_bib81","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2022.05.036","article-title":"Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer","volume":"77","author":"Hogdall","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib82","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4251\/wjgo.v13.i5.332","article-title":"Liquid biopsy in cholangiocarcinoma: current status and future perspectives","volume":"13","author":"Rompianesi","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib83","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.omtn.2022.12.012","article-title":"Exosomal circ-PTPN22 and circ-ADAMTS6 mark T cell exhaustion and neutrophil extracellular traps in Asian intrahepatic cholangiocarcinoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.ajpath.2024.06.013_bib84","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.06.013_bib85","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10147-024-02493-4","article-title":"Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay","volume":"29","author":"Hashimoto","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib86","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajpath.2024.06.013_bib87","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1245\/s10434-023-13126-x","article-title":"Optimizing circulating tumour DNA use in the perioperative setting for intrahepatic cholangiocarcinoma: diagnosis, screening, minimal residual disease detection and treatment response monitoring","volume":"30","author":"Choi","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib88","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib89","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/cancers14010233","article-title":"Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing","volume":"14","author":"Csoma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib90","article-title":"Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors","volume":"6","author":"Lapin","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib92","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fonc.2018.00212","article-title":"A review of circulating tumor DNA in hepatobiliary malignancies","volume":"8","author":"Mody","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib93","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.33230","article-title":"Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers","volume":"148","author":"Okamura","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2024.06.013_bib94","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.3390\/cancers14174281","article-title":"Prevalence of ARID1A mutations in cell-free circulating tumor DNA in a cohort of 71,301 patients and association with driver co-alterations","volume":"14","author":"Kurzrock","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib95","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.06.013_bib96","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-023-00470-7","article-title":"Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA","volume":"13","author":"Astier","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.1609879","article-title":"Genomic profiling of blood-derived circulating tumor DNA from patients with advanced biliary tract cancer","volume":"27","author":"Chen","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ajpath.2024.06.013_bib98","article-title":"Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - the promise of DNA methylation and molecular biomarkers","volume":"2","author":"Vedeld","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib99","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.3390\/cancers14194598","article-title":"The clinical impact of methylated homeobox A9 ctDNA in patients with non-resectable biliary tract cancer treated with erlotinib and bevacizumab","volume":"14","author":"Andersen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib100","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib101","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.3390\/cancers14235969","article-title":"The role of single-nucleotide polymorphisms in cholangiocarcinoma: a systematic review","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-240077","article-title":"Intrahepatic cholangiocarcinoma in a non-cirrhotic liver in a patient with homozygous ZZ alpha-1 antitrypsin deficiency","volume":"14","author":"Vuurberg","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib103","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3390\/cells12121663","article-title":"Increased prevalence of alpha-1-antitrypsin deficiency in patients with biliary tract cancer and its associated clinicopathological features","volume":"12","author":"Cornillet","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2024.06.013_bib104","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jhep.2022.09.025","article-title":"Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer","volume":"78","author":"Okawa","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clinre.2018.10.010","article-title":"The diagnostic efficacy of CYFRA21-1 on intrahepatic cholangiocarcinoma: a meta-analysis","volume":"43","author":"Guowei","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib107","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/bs.acr.2022.01.010","article-title":"Matricellular proteins in intrahepatic cholangiocarcinoma","volume":"156","author":"Sirica","year":"2022","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.ajpath.2024.06.013_bib108","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep4.1131","article-title":"Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model","volume":"2","author":"Manzanares","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2024.06.013_bib109","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00000658-199803000-00012","article-title":"Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker","volume":"227","author":"Goydos","year":"1998","journal-title":"Ann Surg"},{"key":"10.1016\/j.ajpath.2024.06.013_bib110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.06.013_bib111","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","article-title":"Metabolic rearrangements in primary liver cancers: cause and consequences","volume":"16","author":"Satriano","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib112","article-title":"Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma","volume":"8","author":"Song","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib113","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/cancers12061644","article-title":"Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: a machine-learning approach","volume":"12","author":"Urman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib114","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/hep.30852","article-title":"Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma","volume":"71","author":"Jia","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1389200216666151103115454","article-title":"Bile acids in physiology, pathology and pharmacology","volume":"17","author":"Marin","year":"2015","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ajpath.2024.06.013_bib116","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.gastrohep.2022.02.005","article-title":"Metabolic-associated fatty liver disease: from simple steatosis toward liver cirrhosis and potential complications: proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)","volume":"45","author":"Gallego-Duran","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib117","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.3390\/cancers15174370","article-title":"Metabolomics of duodenal juice for biliary tract cancer diagnosis","volume":"15","author":"Kishi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib118","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.06.013_bib121","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.3390\/cancers14163921","article-title":"Diagnosis biomarkers of cholangiocarcinoma in human bile: an evidence-based study","volume":"14","author":"Bao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.06.013_bib122","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1038\/s41598-023-27603-6","article-title":"Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.06.013_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117593","article-title":"Bile liquid biopsy in biliary tract cancer","volume":"551","author":"Liu","year":"2023","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ajpath.2024.06.013_bib124","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41416-022-01738-1","article-title":"HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples","volume":"126","author":"Loi","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.06.013_bib125","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/gutjnl-2021-325178","article-title":"Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures","volume":"71","author":"Arechederra","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2024.06.013_bib126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hep.32125","article-title":"Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile","volume":"75","author":"Vedeld","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.06.013_bib127","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","article-title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","volume":"73","author":"Rushbrook","year":"2023","journal-title":"Gut"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024002773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024002773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:09:02Z","timestamp":1772327342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944024002773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002944024002773"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.06.013","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}